ACRUX LIMITED — Capital/Financing Update 2016

Apr 26, 2016

ACRUX (ACR) - ASX ANNOUNCEMENT

27 APRIL 2016

AXIRON NET SALES, QUARTER TO 31 MARCH 2016

==> picture [483 x 10] intentionally omitted <==

Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron net sales of US$37.0 million in its financial results for the quarter ending 31 March 2016, compared to US$39.1 million for the prior corresponding quarter to 31 March, 2015.

Axiron net sales for the previous corresponding quarters are shown in the following table:

Q1 2015	Q2 2015	Q3 2015	Q4 2015
US$39.1m	US$32.4m	US$41.4m	US$41.6m
Q1 2016
US$37.0m

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch[TM] , a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees.

For further information on Acrux, visit www.acrux.com.au

==> picture [541 x 82] intentionally omitted <==